ArticleArchives of Razi Institute2025
Impact of postpartum PGF2α treatment on reproductive performance and prevention of specific uterine disorders in dairy cows.
Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the impact of PGF2α treatment administered after parturition on key reproductive parameters, the incidence of postpartum pathologies, and the resumption of ovarian cyclicity in dairy cows. The study involved two groups of dairy cows: a control group (C, n=20) and an experimental group (E, n=20) that received PGF2α treatment. Postpartum pathologies, ovarian cyclicity, and reproductive performance indicators were compared between the two groups. Postpartum pathologies were observed at a higher rate in the control group, with a 30% prevalence of retained placenta, 20% for both delayed uterine involution and clinical endometritis, and 5% for pyometra. In contrast, the experimental group exhibited a lower incidence: 10% for retained placenta, 5% for delayed uterine involution, 5% for clinical endometritis and 0% for pyometra. Although these results suggest a trend toward a lower incidence of postpartum pathologies in treated cows, the differences were not statistically significant (p>0.05). Regarding the resumption of ovarian cyclicity, the control group showed a resumption rate of only 15%, whereas 65% of the experimental group resumed cyclicity. This yielded an odds ratio of 10.52 and a highly significant p-value (<0.01), indicating that PGF2α treatment effectively hastened the return to normal ovarian function. Reproductive performance was also improved in the experimental group, with first insemination (AI1) success rate of 45% compared to 30% in the control group (OR = 1.93). The waiting period was significantly shorter in the experimental group (73 vs. 98 days, p< 0.001), and both calving-to-fertilization and calving-to-calving intervals were reduced by approximately 31 days (p<0.001). However, the overall reduction in the breeding period remained inconclusive. While PGF2α treatment did not significantly reduce postpartum pathologies, it markedly enhanced the resumption of ovarian cyclicity and improved reproductive intervals in dairy cows, leading to enhanced reproductive efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.